178804-02-9

Upstream product

• 178803-99-1 N-(3,5-dimethoxyphenyl)-4-nitrobenzothioamide 
• 10272-07-8 3.5-dimethoxyaniline 
• 152586-91-9 N-(3,5-dimethoxyphenyl)-4-nitrobenzamide 
• 122-04-3 4-nitro-benzoyl chloride 

Downstream Products

• 178804-14-3 4-(5,7-dimethoxybenzo[d]thiazol-2-yl)aniline 
• 1393815-66-1 2-(4-(5-(3,5-dimethoxyphenyl)-1H-imidazol-1-yl)phenyl)-5,7-dimethoxybenzo[d]thiazole 
• 1393816-18-6 C₂₄H₂₂N₂O₄S 
• 1393815-67-2 2-(4-(5-(3,4-dimethoxyphenyl)-1H-imidazol-1-yl)phenyl)-5,7-dimethoxybenzo[d]thiazole 
• 1393816-19-7 C₂₄H₂₂N₂O₄S 
• 1393815-68-3 5,7-dimethoxy-2-(4-(5-(3,4,5-trimethoxyphenyl)-1H-imidazol-1-yl)phenyl)benzo[d]thiazole 
• 1393816-20-0 C₂₅H₂₄N₂O₅S 

Relevant academic research and scientific papers

Synthesis and reactivity of dimethoxy activated benzothiazoles

A range of 2-substituted-5,7-dimethoxybenzothiazoles and 2-substituted-4,6-dimethoxybenzothiazoles have been synthesized by oxidative cyclization of the corresponding thioamides. These activated benzothiazoles display nucleophilic reactivity at C4 and C7 respectively and undergo formylation, acetylation and related reactions. Some 5,7-dimethoxybenzothiazoles with functionalization in a 2-aryl substituent are also reported as potential precursors for so far unsuccessful formation of macrocycles containing two benzothiazoles and two benzimidazoles.

Synthesis and biological evaluation of cis-restricted triazole/tetrazole mimics of combretastatin-benzothiazole hybrids as tubulin polymerization inhibitors and apoptosis inducers

A series of colchicine site binding tubulin inhibitors were synthesized by the modification of the combretastatin pharmacophore. The ring B was replaced by the pharmacologically relevant benzothiazole scaffolds, and the cis configuration of the olefinic b

2-Arylaminobenzothiazole-arylpropenone conjugates as tubulin polymerization inhibitors

A new series of 2-arylaminobenzothiazole-arylpropenone conjugates 5-6(a-r) was designed, synthesized and investigated for their cytotoxic potency against the various human cancer cell lines. Most of these conjugates exhibited cytotoxic activity and inhibi

2-PHENYL BENZOTHIAZOLE LINKED IMIDAZOLE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF

The present invention provides 2-phenyl benzothiazole linked imidazole compounds of formula A as anti cancer agent against fifty three human cancer cell lines. (General formula A) wherein (II) R=H or OCH3; R1=H, F or OCH3; R2=H or OCH3; R3=H, NH2, F or OCH3; R4=H, NH2 or OCH3; R5=H, NH2, F, CF3 or OCH3; R6=H or OCH3; R7=H or OCH3; R8=H or OCH3.

Benzazole compounds

There are disclosed herein benzazole compounds, exemplified by 2-(4-aminophenyl)benzothiazole and analogues or salts thereof, which exhibit very significant selective cytotoxic activity in respect of tumor cells, especially breast cancer cells, and which provide potentially useful chemotherapeutic agents for treatment of breast cancer.

Antitumor benzothiazoles. 3. Synthesis of 2-(4- aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo

A new series of 2-(4-aminophenyl)benzothiazoles substituted in the phenyl ring and benzothiazole moiety has been synthesized by simple, high- yielding routes. The parent molecule 5a shows potent inhibitory activity in vitro in the nanomolar range against a panel of human breast cancer cell lines, but is inactive (IC50 > 30 μM) against other cell types: activity against the sensitive breast lines MCF-7 and MDA 468 is characterized by a biphasic dose-response relationship. Structure-activity relationships derived using these cell types has revealed that activity follows the heterocyclic sequence benzothiazole > benzoxazole >> benzimidazole and that 2-(4-aminophenyl)benzothiazoles bearing a 3'-methyl- 9a, 3'-bromo- 9c, 3'- iodo- 9f, and 3'-chloro-substituent 9i are especially potent and their activity extends to ovarian, lung, and renal cell lines. Four compounds have been evaluated in vivo against human mammary carcinoma models in nude mice. Compound 9a showed the most potent growth inhibition against the ER+ (MCF- 7 and BO) and ER- (MT-1 and MT-3) tumors. Our efforts to identify a pharmacological mechanism of action for these intriguing compounds have not, as yet, been successful.